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Objective. Sickle cell disease (SCD) is a disease that requires a significant degree of medical intervention, and family physicians
are one potential provider of care for patients who do not have access to specialists. The extent to which family physicians are
comfortable with the treatment of and concerned about potential complications of SCD among their patients is unclear. Our
purpose was to examine family physician’s attitudes toward SCD management.Methods. Data was collected as part of the Council
of Academic Family Medicine Educational Research Alliance (CERA) survey in the United States and Canada that targeted family
physicians who were members of CERA-affiliated organizations. We examined attitudes regarding management of SCD. Results.
Overall, 20.4% of respondents felt comfortable with treatment of SCD. There were significant differences in comfort level for
treatment of SCD patients depending on whether or not physicians had patients who had SCD, as well as physicians who had more
than 10% African American patients. Physicians also felt that clinical decision support (CDS) tools would be useful for treatment
(69.4%) and avoiding complications (72.6%) inmanaging SCDpatients.Conclusions. Family physicians are generally uncomfortable
with managing SCD patients and recognize the utility of CDS tools in managing patients.
1. Introduction
Sickle cell disease (SCD) affects millions of people through-
out theworld and is particularly common among thosewhose
ancestors came from sub-Saharan Africa; Spanish-speaking
regions in the Western Hemisphere (South America, the
Caribbean, and Central America); Saudi Arabia; India; and
Mediterranean countries such as Turkey, Greece, and Italy. It
is estimated that SCD affects 90,000 to 100,000 Americans,
and sickle cell trait occurs among 1 in 12 African Americans
[1].
Patients with sickle cell disease require comprehensive
care including preventive interventions, pain management,
hydroxyurea, and blood transfusions [2]. Further, compli-
cations of transfusions like iron overload are common and
have significant consequences like cirrhosis, heart failure, and
death [3, 4]. Due to the complex and disabling nature of sickle
cell disease, appropriate ambulatory management is critical
to avoid acute pain and vasoocclusive episodes and hospi-
talizations. One estimate has suggested that annually, United
States’ average hospitalization costs for SCD are $6,223 per
hospitalization [5]. Interventions designed to prevent SCD
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complications and avoid hospitalizations are estimated to
have substantial economic benefits, as the discounted lifetime
cost of care averages $460,151 per patient with SCD [6].
Translation of evidence from clinical trials into health
care delivery for patients with sickle cell disease needs
to happen. For example, hydroxyurea, the only currently
available FDA-approved medication for preventing compli-
cations of sickle cell disease, is effective. The Multicenter
Study of Hydroxyurea in Patients with Sickle Cell Anemia,
a multicenter landmark randomized controlled trial, clearly
demonstrated that use of hydroxyurea by adult patients with
sickle cell anemia resulted in a significant reduction in the
frequency of pain crises, hospitalizations, and red blood
cell transfusions [7]. A nine-year follow-up observational
study revealed a reduction in mortality for patients taking
hydroxyurea compared to study participants not taking the
medication [8]. However, hydroxyurea is underused [9]. In
one study at three teaching hospitals in the southeastern
United States only 42% of adult SCD patients were taking
hydroxyurea [10].
The extent to which family physicians are comfortable
implementing such advances in treatment for SCD in clinical
practice is unclear. Little information exists on current
practice and use of therapies for children and adults with SCD
in this setting. There are many factors that could influence
a physician’s attitudes toward SCD. For example, SCD is
more prevalent among African Americans, and so physicians
whose practices are comprised of larger proportions of
African Americans might be more attuned to issues such as
SCD that disproportionately affect their patient population.
Physicians who have active patients with SCD may be more
familiar and more comfortable with SCD patients and the
disease. Physician age is another factor that may influence
comfort with managing and treating SCD patients. Younger
physicians may have a greater recall of details regarding less
common diseases that are infrequently seen in practice. In
addition, age may influence interest in use of technology in
the clinical encounter. Because of the significant impact on
morbidity andmortality and health care costs associated with
inappropriate management of SCD [11–14], it is important to
better understand current practice. A better understanding of
sickle cell management and complication knowledge deficits
of physicians will help to drive interventions like clinical
decision support CDS systems [15, 16] and primary-specialty
physician comanagement programs to improve care for the
vulnerable population of people with SCD. Less common
diseases such as SCD are prime candidates for CDS tools, as
they can support physician knowledge and management of
diseases that they do not encounter regularly in practice.
2. Methods
This study is an analysis of a survey conducted as part of the
Council of Academic Family Medicine Educational Research
Alliance (CERA). CERA is a joint initiative of all four
major US academic family medicine organizations (Society
of Teachers of Family Medicine (STFM), North American
Primary Care Research Group (NAPCRG), Association of
Departments of Family Medicine (ADFM), and Association
of Family Medicine Residency Directors (AFMRD)).
The investigators submitted questions related to SCD
practice and treatment for inclusion in the CERA survey.
The survey was designed as an omnibus survey incorporating
several distinct subprojects focusing on different topic areas.
Practicing physician members of the CERA-affiliated organi-
zations in the United States were identified for participation.
Although these organizations are all headquartered in the
United States, there are some members from outside the
United States. This survey was limited to US based members.
Since some individuals were members of multiple organi-
zations, unique individuals were selected for the sampling
frame.The study was approved by the American Academy of
Family Physicians Institutional Review Board.
The survey was conducted between November, 2013, and
January, 2014, and sent to 3158 physicians who are members
of Council of Academic Family Medicine organizations. The
potential respondents were surveyed electronically with an
initial email invitation for participation. The survey was
conducted through the infrastructure of STFM. The survey
was introduced in an email that included a personalized
greeting, a letter signed by the presidents of each of the four
participating organizations urging participation, and a link to
the survey. Nonrespondents were sent two follow-up emails
encouraging participation. As the survey was structured as
an omnibus survey, with several subprojects containedwithin
the overall survey, it was possible for respondents to skip
questions.
The survey questions for this study were developed
following a review of the literature to identify key concepts
and issues suggesting the need for additional knowledge.The
attitudinal outcomes of interest were physicians’ responses
to questions related to their “comfort managing sickle cell
disease patients,” “complication concerns,” “willingness to
manage patients,” and “usefulness of CDS tools”.
2.1. Comfort Managing Patients. Comfort with overall man-
agement and pain management of SCD patients was assessed
using a Likert scale (somewhat/very uncomfortable, neutral,
and somewhat/very comfortable). Comfort with managing
SCD patients with specific treatment options (red blood cell
transfusions, hematopoietic stem cell transplant (HSCT), and
hydroxyurea) was assessed as well. These options represent
the main treatments available for SCD patients and represent
a wide range of usage in practice, from relatively common
pain management to the less frequently used HSCT.
2.2. Complication Concerns. Concern for SCD complica-
tions was assessed using physician’s stated level of concern
(somewhat/very unconcerned, neutral, and somewhat/very
concerned) for known complications of SCD, including iron
overload, stroke, atherosclerosis, and pneumonia.
2.3. Willingness to Comanage Patients with a Specialist.
Willingness to comanage an SCD patient was assessed for
pediatric and adult patients (somewhat/very likely, neutral,
and somewhat/very unlikely).
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2.4. Use of Clinical Decision Support Tools on SCD Care. The
willingness of a physician to self-manage care of SCDpatients
with the assistance of a CDS tool was assessed for pediatric
and adult patients (somewhat/very unlikely, neutral, and
somewhat/very likely).The perceived utility of CDS tools was
assessed for diagnosis of SCD, treatment of SCD, and the
avoidance of complications (somewhat/very useful, neutral,
and somewhat/very not useful).
2.5. Demographics. We collected data on age, race/ethnicity,
academic rank, primary physician duty, patient time, time
in clinic, proportion of patients who are African American,
number of patients with SCD, and proportion of patients
with SCD who are under 19 years of age from all survey
participants (Table 1).
3. Analysis
We computed descriptive statistics to understand the general
practice patterns of the survey respondents and their overall
attitudes toward SCD and SCD treatment.We collapsed all of
the Likert scale questions into two categories, examining the
difference between those who answered the questions with a
positive answer (somewhat and very comfortable, likely, and
concerned) and respondents who felt neutral or responded
negatively. Next, we conducted bivariate analyses with chi-
square tests to compare attitudes based on respondents’
proportion of African American patients (less than 10%
versus 10% or greater), as well as by the presence of SCD
patients in the physician’s practice, and by physician age
(younger than 50 versus 50 and older). We judged statistical
significance at 𝑃 ≤ 0.05.
4. Results
The overall number of surveys returned was 1060 for a 34%
response rate. We analyzed data from the 1042 physicians
who responded to at least one question on the SCD section
of the survey. Table 1 shows demographic information about
these physician respondents. The majority of physicians had
no SCD patients, and only 15.9% had more than five SCD
patients. Slightly less than half of the surveyed physicians
spent 3 or more half-days in clinic. Overall, few physicians
had a substantial proportion of African American patients,
with only 25.7% reporting 25% or more African American
patients. Table 2 shows the bivariate analysis for comfort
managing patients, complications concerns, willingness to
comanage patients, and thoughts on CDS tools for the full
population. Table 3 shows differences between physicians
with <10% African American patients and physicians with
10% or more African American patients. Table 4 shows
differences between physicians with no active SCD patients
and those with active SCD patients.There were no significant
differences between groups in relation to perceived utility of
CDS for helping direct treatment or avoiding complications.
A majority of all groups felt that CDS would be useful.
There were several significant differences between physi-
cians under age 50 and those aged 50 and older. A smaller
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7+ half days 5.1















percentage of younger physicians were comfortable with
overall management of SCD patients (15.7%) compared to
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Table 2: Physician perceptions of SCD, full sample.
Full sample
Comfort managing patients Comfortable
Overall management, % 20.4
RBC transfusions, % 30.8
HSCT, % 0.6
Hydroxyurea treatment, % 20.5
Pain management, % 47.8
Complication concerns Concerned




Willing to comanage patient with specialist Likely
Pediatric patients, % 79.7
Adult patients, % 67.8
Impact of CDS on willingness to manage SCD
patients Likely
Pediatric patients, % 25.6
Adult patients, % 34.1




older physicians (25.1%, 𝑃 = 0.0002). A larger percentage
of physicians who were older expressed concern for iron
overload, with 66.1% expressing concern, in contrast to 55.8%
of younger physicians (𝑃 = 0.0009). A greater percent-
age of younger physicians were more willing to comanage
adult SCD patients (70.8%) than older physicians (64.3%,
𝑃 = 0.03). A greater percentage of younger physicians
were willing to independently manage adult SCD patients
with the assistance of a CDS tool, with 38.1% of younger
physicians indicating an increased likelihood, compared to
29.9% of older physicians (𝑃 = 0.007). A larger percentage of
younger physicians saw the utility of CDS tools, with 72.5%
indicating that CDS tools would be useful for the treatment
of patients, compared with 66.6% of older physicians (𝑃 =
0.04). In addition, a greater percentage of younger physicians
considered CDS tools useful for avoiding complications than
older physicians (77.7% versus 67.2%, 𝑃 = 0.0002).
5. Discussion
The results of this study indicate that academic family
physicians have few SCD patients in their patient panel.
More importantly, the results indicate that there are concerns
among these primary care physicians regarding their ability
to manage SCD and its complications. That said, there seems
to be general agreement that a CDS tool may play a beneficial
role in managing these patients especially among younger
physicians.
As might be expected, more frequent interaction with
SCD patients or African American patients, those at higher
risk for SCD, was associated with greater comfort in manag-
ing SCD patients. Age of the physician was related to comfort
managing these patients in several important ways. Older
physicians appeared more comfortable with treatment and
management of a complication like iron overload, potentially
reflecting lifetime exposure to this patient population, while
younger physicians were more likely to embrace tools that
would assist them in managing patients independently.
A CDS for managing SCD received significant endorse-
ment from this sample of academic family physicians. CDS
tools have been successfully utilized in the management of
care for a number of conditions [15, 16]. It appears that a
CDS would have utility for both managing treatment and
complications. Younger physicians were more likely to see a
CDS to be particularly useful. As electronic health records
become more commonplace in primary care the ability to
implement a CDS for less common diseases is increased.
Although there is evidence of alert fatigue with CDS for
common conditions [17], the use of a CDS for SCDwould not
likely be perceived as an annoyance but rather as a benefit.
This study is the first study to report on family physician’s
comfort and attitudes with managing SCD. In addition to
this strength, there are several limitations to this study. The
first is that although the survey is based on a national sample
of family physicians, a group that would likely encounter
SCD child and adult patients, the group under study is all in
academic settings. Consequently, in terms of clinical practice
most academic family physicians do not practice full time.
This amount of clinical practice may potentially affect their
comfort with SCD. Second, even though the sample size
allows us to examine responses to more than 1,000 respon-
dents, the response rate of 34% is not exceptionally high.
Thus, there may be some bias in the participants based on
their comfort and interest in the questions. The low response
rate may have been a result of the time of year the survey was
sent out, as it was administered during the holiday season.
As was clear from the practice characteristics, SCD patients
are not common in the patient panels of the respondents. It is
possible that individuals with no SCDpatients were less likely
to participate in a study on managing SCD patients. Finally,
the level of training that physicians received for SCD was not
assessed. Physician attitudes regarding SCDmanagement are
likely to be influenced not only by SCD patients in their care,
but also by the amount of SCD-specific training they received.
In conclusion, although academic family physicians rec-
ognize issues in their comfort and ability to manage SCD
patients they endorse the potential utility of CDS. Future
studies could evaluate whether a CDS system could improve
the quality of care and control of complications like iron
overload for this vulnerable population.
Disclaimer
The findings and conclusions in this report are those of the
authors and do not necessarily represent the official position
of the Centers for Disease Control and Prevention.
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African American patients 𝑃 value
Comfort managing patients Comfortable Comfortable
Overall management, % 12.7 27.0 <0.0001
RBC transfusions, % 25.4 35.6 0.0006
HSCT, % 0.2 1.0 0.14
Hydroxyurea treatment, % 16.1 24.3 0.002
Pain management, % 42.4 52.6 0.001
Complication concerns Concerned Concerned
Iron overload, % 58.6 62.8 0.18
Stroke, % 75.3 79.5 0.12
Atherosclerosis, % 43.5 48.0 0.15
Pneumonia, % 68.0 74.3 0.03
Willing to comanage patient with specialist Likely Likely
Pediatric patients, % 78.2 80.9 0.31
Adult patients, % 69.8 66.0 0.20
Impact of CDS on willingness to manage SCD patients Likely Likely
Pediatric patients, % 24.0 27.0 0.27
Adult patients, % 31.3 36.6 0.08
Perceived utility of CDS for SCD patient care Useful Useful
Diagnosis 27.2 19.2 0.003
Treatment 68.1 70.4 0.45
Avoiding complications 70.2 74.5 0.13
Table 4: Physician perceptions of SCD by number of patients with SCD.
Physicians with no SCD patients Physicians with 1 ormore SCD patients 𝑃 value
Comfort managing patients Comfortable Comfortable
Overall management, % 9.8 36.1 <0.0001
RBC transfusions, % 21.8 45.1 <0.0001
HSCT, % 0.2 1.3 0.026
Hydroxyurea treatment, % 14.2 30.4 <0.0001
Pain management, % 39.0 61.7 <0.0001
Complication concerns Concerned Concerned
Iron overload, % 58.5 64.3 0.07
Stroke, % 75.3 80.7 0.04
Atherosclerosis, % 45.4 46.7 0.70
Pneumonia, % 67.3 77.6 0.0004
Willing to comanage patient with specialist Likely Likely
Pediatric patients, % 76.5 84.1 0.003
Adult patients, % 70.1 64.5 0.07
Impact of CDS on willingness to manage SCD patients Likely Likely
Pediatric patients, % 23.5 28.8 0.06
Adult patients, % 30.8 38.7 0.01
Perceived utility of CDS for SCD patient care Useful Useful
Diagnosis 26.9 17.0 0.0003
Treatment 68.9 70.1 0.71
Avoiding complications 72.2 73.2 0.72
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